Back to top

Image: Bigstock

Pacific Biosciences of California Inc.

Read MoreHide Full Article

Pacific Biosciences ended the fourth quarter of 2017 on an impressive note, with narrower loss reported per share and revenues beating the Zacks Consensus Estimate. Solid contribution from Consumable revenue platform, generated from sequel systems has been consistently acting as a growth driver for Pacific Biosciences. Sales momentum in China continued to be strong on the company’s recent receipt of an order for 10 sequel systems from the premier sequencing service provider, BGI. The 2018 guidance looks encouraging. Of the major concerns, the DNA sequencing market breeds stiff competition with several established players establishing dominance. Sales in Europe declined considerably. Aggressive rivalry in this niche space is a headwind. Also, higher operating expenses are likely to mar prospects.

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Pacific Biosciences of California, Inc. (PACB) - free report >>

Published in